RECKITT BENCKISER LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1889-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.lysol.com
Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 552
- Registration Number
- NCT03725085
Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 36
- Registration Number
- NCT03649750
Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03642873
Study to Evaluate the Pharmacokinetics of Guaifenesin in Adults and Adolescents
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03633448
Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03633487
Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 122
- Registration Number
- NCT01986361
- Locations
- 🇺🇸
University of Connecticut - Student Health Services, Storrs, Connecticut, United States
Evaluation of Tolerance and Acceptability of a Coated Condom
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 50
- Registration Number
- NCT01619397
- Locations
- 🇬🇧
Alba Science Ltd, 24 Brought Street, Edinburgh, United Kingdom
Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 2810
- Registration Number
- NCT01537081
- Locations
- 🇺🇸
Reckitt Benckiser Study Site, Spokane, Washington, United States
Safety & Performance Study of Verruca Treatment Device
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 35
- Registration Number
- NCT01536834
- Locations
- 🇬🇧
Mr. Andrew Ryals, Wakefield, Yorkshire, United Kingdom
Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-27
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 678
- Registration Number
- NCT01229449
- Locations
- 🇺🇸
Premier Research, Austin, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath